Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.
Rigel Pharmaceuticals Inc. sees positive signs in a failed Phase II study of its spleen tyrosine kinase (SYK) inhibitor Tavalisse (fostamatinib) and says it will consider next steps for development with potential partners.
The company reported topline data on April 3 from a Phase II study evaluating fostamatinib in immunoglobulin A nephropathy (IgAN), an autoimmune disease of the kidneys that progresses to end-stage renal failure
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
